Early Access

10-QPeriod: Q1 FY2021

CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2021

Filed May 4, 2021For Securities:CVS

Summary

CVS Health Corporation reported solid financial results for the first quarter ended March 31, 2021, demonstrating revenue growth across all segments and a notable increase in net income. Total revenues rose by 3.5% year-over-year, reaching $69.1 billion, driven by growth in Premiums and Services. Net income attributable to CVS Health increased by 10.8% to $2.22 billion, with diluted earnings per share rising to $1.68 from $1.53 in the prior year period. The company's integrated business model, spanning Health Care Benefits, Pharmacy Services, and Retail/LTC, continues to show resilience, with each segment contributing to the overall performance. The company's liquidity remains strong, evidenced by positive cash flows from operating activities, although slightly lower than the prior year due to strategic payment timing. Management highlighted the company's ability to navigate the ongoing impacts of COVID-19, with efforts focused on cost savings and operational efficiencies expected to continue benefiting the company. Despite ongoing litigation and regulatory risks, CVS Health expressed confidence in its ability to manage these, with no individual or aggregate material adverse effects anticipated from these matters at this time.

Financial Statements
Beta
Revenue$69.10B
Cost of Revenue$40.89B
Gross Profit$28.20B
Operating Expenses$65.52B
Operating Income$3.58B
Interest Expense$657.00M
Net Income$2.22B
EPS (Basic)$1.69
EPS (Diluted)$1.68
Shares Outstanding (Basic)1.31B
Shares Outstanding (Diluted)1.32B

Key Highlights

  • 1Total revenues increased by 3.5% to $69.1 billion for the first quarter of 2021 compared to the same period in 2020.
  • 2Net income attributable to CVS Health grew by 10.8% to $2.22 billion, resulting in diluted earnings per share of $1.68.
  • 3The Health Care Benefits segment saw a 6.7% increase in total revenues, primarily driven by growth in government business and a higher Medical Benefit Ratio (MBR).
  • 4Pharmacy Services segment revenue increased by 3.8%, benefiting from growth in specialty pharmacy and improved purchasing economics, although impacted by price compression.
  • 5Retail/LTC segment revenue saw a modest 2.3% increase, driven by COVID-19 testing and vaccinations, partially offset by lower front store sales and reimbursement pressures.
  • 6Operating income increased by 3.4% to $3.58 billion, reflecting growth in Pharmacy Services and Health Care Benefits, partially offset by a decline in Retail/LTC.
  • 7The company maintained a strong balance sheet with total assets of $229.6 billion and total liabilities of $158.4 billion, while its cash position remained robust at $5.6 billion.

Frequently Asked Questions